The prevalence rate of cough condition is definitely around at 15 percent in China. It is estimated that over 50 million Chinese patients are seeking cough treatment, caused by respiratory disorders mainly. The market size of pharmaceutical product to address cough condition is estimated approximately $2 billion each year with an annual development rate of over 10 percent in China.. China Aoxing submits an NDA to the China SFDA for its Codeine Phosphate China Aoxing Pharmaceutical Business, Inc. , a pharmaceutical organization focusing on research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it provides submitted a new drug software to the China Condition Food and Drug Administration for its Codeine Phosphate, a compound oral solution for the treating acute moderate to severe cough.Half of the group had Parkinson’s disease; the spouse did not possess Parkinson’s disease. Among both groups, nearly fifty % used high blood circulation pressure medications, such as for example calcium channel blockers, ACE inhibitors, AT II antagonists and beta blockers. Related StoriesStudy shows antipsychotic medication increases death risk in sufferers with Parkinson's disease psychosisReview finds little evidence between alcohol PD and intake incidenceGene therapy prevents neuronal death, disease results in experimental style of PDThe research found people who were currently long-term users of calcium channel blockers to treat high blood circulation pressure lowered their threat of Parkinson’s disease by 23 % compared to people who didn’t take the drugs.